Sammendrag
Naltrexone is an opioid receptor antagonist that blocks the effects of opioids such as heroin and morphine. Naltrexone has no abuse potential, mild and transient side effects and thus appears an ideal pharmacotherapy for opioid dependence. Limited compliance with oral naltrexone treatment is a known drawback.
Several naltrexone implant and injectable depot formulations are being investigated and provide naltrexone release for at least one month. During the last couple of years several reports on new formulations have been published. This presentation gives an update on the systematic Cochrane review first published in 2008 on naltrexone injectables and implants for opioid dependence.
The new systematic search was conducted in August 2010. To evaluate effectiveness only randomised-controlled trials (RCTs) were included. Reviewers independently evaluated the reports, rated methodological quality and extracted data. When appropriate, meta-analyses were performed for pre-specified outcome measures. The systematic search identified 685 reports as possibly relevant. The findings from the RCTs that were included will be presented at the meeting.
Vis fullstendig beskrivelse